Clinical Trial Update: Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating a first-line treatment regimen of trastuzumab deruxtecan, pembrolizumab, and platinum-based chemotherapy for HER2-ov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan) (trastuzumab deruxtecan)
• Keytruda (Pembrolizumab) (pembrolizumab)
• Platinum-based chemotherapy (first-line regimen) (platinum-based chemotherapy)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING